Metcalf Foundation

Nonprofit Technology

CyberGrants | June 07, 2022

Today marks the beginning of the Social Impact Leadership Conference (SILC), hosted by CyberGrants, a Bonterra company. The event runs June 6-8 and is being held in Austin, Texas. For the first time since 2019, SILC returns in-person to bring together the corporate social responsibility (CSR) community, offering presentations from industry thought leaders, breakout sessions with professionals representing grant making, workplace giving, volunteerism, nonprofit engagement, and netw...

Fundraising

PRNewswire | June 07, 2023

For more than 40 years the main treatment for pediatric osteosarcoma has not changed. Patients with this type of aggressive bone cancer, most often diagnosed in teens, are in desperate need of new options. Fewer than 30% of patients survive when osteosarcoma has spread beyond the primary tumor at diagnosis. To make a significant impact for kids fighting osteosarcoma, five funding partners have banded together with St. Baldrick's to support a new grant - The Fight Osteosarcom...

Urban Ventures | August 04, 2020

Urban Ventures, a South Minneapolis-based nonprofit, today announced it has received a $100,000 donation from Young Living, a leading essential oils and wellness company. The goal of Urban Ventures is to send every child within the 25-block core area of downtown Minneapolis to college or some form of postsecondary education by 2040. The organization believes the single greatest mechanism for breaking the cycle of poverty is through education. This generous donation will provide resources t...

Fundraising

Lung Cancer Research Foundation | February 01, 2022

The Lung Cancer Research Foundation (LCRF) and KRAS Kickers are excited to announce a partnership aimed at raising much needed funds for research. Together they to pledge to fund at least one two-year grant in 2022 with the goal of improving outcomes for people with KRAS-mutant lung cancer. KRAS is the most common mutation in non-small cell lung cancer patients, making up about 30% of driver mutations in lung adenocarcinoma. KRAS was considered undruggable until last year's FD...